Medical - Healthcare Information Services
Compare Stocks
5 / 10Stock Comparison
PINC vs OMI vs HSIC vs MCK vs HCAT
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Distribution
Medical - Distribution
Medical - Distribution
Medical - Healthcare Information Services
PINC vs OMI vs HSIC vs MCK vs HCAT — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Medical - Healthcare Information Services | Medical - Distribution | Medical - Distribution | Medical - Distribution | Medical - Healthcare Information Services |
| Market Cap | $2.34B | $171M | $8.09B | $92.15B | $113M |
| Revenue (TTM) | $1.00B | $2.76B | $13.18B | $403.43B | $311M |
| Net Income (TTM) | $-24M | $-1.10B | $398M | $4.76B | $-178M |
| Gross Margin | 72.6% | — | 29.1% | 3.6% | 48.7% |
| Operating Margin | -0.0% | 1.0% | 5.8% | 1.5% | -51.7% |
| Forward P/E | 20.8x | 2.3x | 13.3x | 19.3x | 14.1x |
| Total Debt | $282M | $320M | $3.69B | $7.39B | $20M |
| Cash & Equiv. | $84M | $282M | $156M | $5.69B | $51M |
PINC vs OMI vs HSIC vs MCK vs HCAT — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | Nov 25 | Return |
|---|---|---|---|
| Premier, Inc. (PINC) | 100 | 81.2 | -18.8% |
| Owens & Minor, Inc. (OMI) | 100 | 50.1 | -49.9% |
| Henry Schein, Inc. (HSIC) | 100 | 104.1 | +4.1% |
| McKesson Corporation (MCK) | 100 | 511.3 | +411.3% |
| Health Catalyst, In… (HCAT) | 100 | 11.9 | -88.1% |
Price return only. Dividends and distributions are not included.
Quick Verdict: PINC vs OMI vs HSIC vs MCK vs HCAT
Each card shows where this stock fits in a portfolio — not just who wins on paper.
PINC is the #2 pick in this set and the best alternative if income & stability and sleep-well-at-night is your priority.
- Dividend streak 1 yrs, beta 0.07, yield 3.0%
- Lower volatility, beta 0.07, Low D/E 18.4%, current ratio 0.64x
- Beta 0.07, yield 3.0%, current ratio 0.64x
- 3.0% yield, 1-year raise streak, vs MCK's 0.4%, (3 stocks pay no dividend)
OMI ranks third and is worth considering specifically for value.
- Lower P/E (2.3x vs 14.1x)
HSIC is the clearest fit if your priority is quality.
- 3.0% margin vs HCAT's -57.2%
MCK carries the broadest edge in this set and is the clearest fit for growth exposure and long-term compounding.
- Rev growth 16.2%, EPS growth 14.9%, 3Y rev CAGR 10.8%
- 348.1% 10Y total return vs HSIC's 5.3%
- PEG 0.49 vs HSIC's 4.21
- 16.2% revenue growth vs OMI's -74.2%
Among these 5 stocks, HCAT doesn't own a clear edge in any measured category.
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 16.2% revenue growth vs OMI's -74.2% | |
| Value | Lower P/E (2.3x vs 14.1x) | |
| Quality / Margins | 3.0% margin vs HCAT's -57.2% | |
| Stability / Safety | Beta 0.04 vs HCAT's 2.05 | |
| Dividends | 3.0% yield, 1-year raise streak, vs MCK's 0.4%, (3 stocks pay no dividend) | |
| Momentum (1Y) | +24.0% vs OMI's -71.1% | |
| Efficiency (ROA) | 5.7% ROA vs OMI's -44.9%, ROIC 5.4% vs 1.8% |
PINC vs OMI vs HSIC vs MCK vs HCAT — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
PINC vs OMI vs HSIC vs MCK vs HCAT — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
MCK leads in 2 of 6 categories
HSIC leads 1 • OMI leads 1 • PINC leads 0 • HCAT leads 0 • 2 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
HSIC leads this category, winning 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
MCK is the larger business by revenue, generating $403.4B annually — 1296.6x HCAT's $311M. HSIC is the more profitable business, keeping 3.0% of every revenue dollar as net income compared to HCAT's -57.2%. On growth, HSIC holds the edge at +7.7% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $1.0B | $2.8B | $13.2B | $403.4B | $311M |
| EBITDAEarnings before interest/tax | $118M | $277M | $1.1B | $6.8B | -$110M |
| Net IncomeAfter-tax profit | -$24M | -$1.1B | $398M | $4.8B | -$178M |
| Free Cash FlowCash after capex | $265M | -$353M | $561M | $6.0B | -$5M |
| Gross MarginGross profit ÷ Revenue | +72.6% | — | +29.1% | +3.6% | +48.7% |
| Operating MarginEBIT ÷ Revenue | -0.0% | +1.0% | +5.8% | +1.5% | -51.7% |
| Net MarginNet income ÷ Revenue | -2.4% | -39.8% | +3.0% | +1.2% | -57.2% |
| FCF MarginFCF ÷ Revenue | +26.4% | -12.8% | +4.3% | +1.5% | -1.5% |
| Rev. Growth (YoY)Latest quarter vs prior year | -3.3% | -146.3% | +7.7% | +6.0% | -6.2% |
| EPS Growth (YoY)Latest quarter vs prior year | -70.0% | +4.5% | +14.9% | +37.0% | -2.9% |
Valuation Metrics
OMI leads this category, winning 3 of 7 comparable metrics.
Valuation Metrics
At 21.6x trailing earnings, HSIC trades at a 83% valuation discount to PINC's 128.5x P/E. Adjusting for growth (PEG ratio), MCK offers better value at 0.75x vs HSIC's 6.84x — a lower PEG means you pay less per unit of expected earnings growth.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $2.3B | $171M | $8.1B | $92.1B | $113M |
| Enterprise ValueMkt cap + debt − cash | $2.5B | $209M | $11.6B | $93.8B | $82M |
| Trailing P/EPrice ÷ TTM EPS | 128.45x | -0.16x | 21.56x | 29.25x | -0.62x |
| Forward P/EPrice ÷ next-FY EPS est. | 20.79x | 2.31x | 13.26x | 19.28x | 14.15x |
| PEG RatioP/E ÷ EPS growth rate | — | — | 6.84x | 0.75x | — |
| EV / EBITDAEnterprise value multiple | 21.35x | 1.70x | 10.87x | 18.74x | — |
| Price / SalesMarket cap ÷ Revenue | 2.31x | 0.06x | 0.61x | 0.26x | 0.36x |
| Price / BookPrice ÷ Book value/share | 1.70x | — | 1.79x | — | 0.45x |
| Price / FCFMarket cap ÷ FCF | 7.33x | — | 14.12x | 17.63x | — |
Profitability & Efficiency
MCK leads this category, winning 6 of 9 comparable metrics.
Profitability & Efficiency
MCK delivers a 3.0% return on equity — every $100 of shareholder capital generates $3 in annual profit, vs $-21 for OMI. HCAT carries lower financial leverage with a 0.08x debt-to-equity ratio, signaling a more conservative balance sheet compared to HSIC's 0.77x. On the Piotroski fundamental quality scale (0–9), MCK scores 6/9 vs OMI's 2/9, reflecting solid financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | -1.6% | -21.1% | +8.2% | +3.0% | -54.7% |
| ROA (TTM)Return on assets | -0.8% | -44.9% | +3.6% | +5.7% | -27.4% |
| ROICReturn on invested capital | +0.0% | +1.8% | +7.1% | +5.4% | -32.9% |
| ROCEReturn on capital employed | +0.0% | +1.3% | +9.8% | +30.5% | -34.0% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 2 | 4 | 6 | 6 |
| Debt / EquityFinancial leverage | 0.18x | — | 0.77x | — | 0.08x |
| Net DebtTotal debt minus cash | $198M | $38M | $3.5B | $1.7B | -$31M |
| Cash & Equiv.Liquid assets | $84M | $282M | $156M | $5.7B | $51M |
| Total DebtShort + long-term debt | $282M | $320M | $3.7B | $7.4B | $20M |
| Interest CoverageEBIT ÷ Interest expense | 1.13x | -0.12x | 4.59x | 33.79x | -4.79x |
Total Returns (Dividends Reinvested)
MCK leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in MCK five years ago would be worth $38,689 today (with dividends reinvested), compared to $299 for HCAT. Over the past 12 months, PINC leads with a +24.0% total return vs OMI's -71.1%. The 3-year compound annual growth rate (CAGR) favors MCK at 27.3% vs OMI's -49.9% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | — | -3.4% | -8.2% | -8.5% | -30.3% |
| 1-Year ReturnPast 12 months | +24.0% | -71.1% | +5.9% | +4.6% | -59.9% |
| 3-Year ReturnCumulative with dividends | +14.8% | -87.4% | -11.7% | +106.4% | -86.9% |
| 5-Year ReturnCumulative with dividends | -9.2% | -93.5% | -12.5% | +286.9% | -97.0% |
| 10-Year ReturnCumulative with dividends | -4.6% | -86.2% | +5.3% | +348.1% | -95.9% |
| CAGR (3Y)Annualised 3-year return | +4.7% | -49.9% | -4.0% | +27.3% | -49.2% |
Risk & Volatility
Evenly matched — PINC and MCK each lead in 1 of 2 comparable metrics.
Risk & Volatility
MCK is the less volatile stock with a 0.04 beta — it tends to amplify market swings less than HCAT's 2.05 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. PINC currently trades 98.2% from its 52-week high vs OMI's 23.5% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.07x | 1.44x | 0.73x | 0.04x | 2.05x |
| 52-Week HighHighest price in past year | $28.79 | $9.55 | $89.29 | $999.00 | $5.06 |
| 52-Week LowLowest price in past year | $20.62 | $1.84 | $61.95 | $637.00 | $0.96 |
| % of 52W HighCurrent price vs 52-week peak | +98.2% | +23.5% | +79.0% | +75.3% | +31.4% |
| RSI (14)Momentum oscillator 0–100 | 65.0 | 46.5 | 39.1 | 16.2 | 63.9 |
| Avg Volume (50D)Average daily shares traded | 0 | 690K | 1.2M | 757K | 720K |
Analyst Outlook
Evenly matched — PINC and MCK each lead in 1 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: PINC as "Hold", OMI as "Hold", HSIC as "Hold", MCK as "Buy", HCAT as "Buy". Consensus price targets imply 78.6% upside for OMI (target: $4) vs -0.0% for PINC (target: $28). For income investors, PINC offers the higher dividend yield at 2.98% vs MCK's 0.36%.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Hold | Hold | Hold | Buy | Buy |
| Price TargetConsensus 12-month target | $28.25 | $4.00 | $86.43 | $1006.50 | $2.50 |
| # AnalystsCovering analysts | 31 | 10 | 32 | 31 | 22 |
| Dividend YieldAnnual dividend ÷ price | +3.0% | — | — | +0.4% | — |
| Dividend StreakConsecutive years of raises | 1 | 0 | 1 | 17 | — |
| Dividend / ShareAnnual DPS | $0.84 | — | — | $2.69 | — |
| Buyback YieldShare repurchases ÷ mkt cap | +17.1% | 0.0% | +10.5% | +3.4% | +4.4% |
MCK leads in 2 of 6 categories (Profitability & Efficiency, Total Returns). HSIC leads in 1 (Income & Cash Flow). 2 tied.
PINC vs OMI vs HSIC vs MCK vs HCAT: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is PINC or OMI or HSIC or MCK or HCAT a better buy right now?
For growth investors, McKesson Corporation (MCK) is the stronger pick with 16.
2% revenue growth year-over-year, versus -74. 2% for Owens & Minor, Inc. (OMI). Henry Schein, Inc. (HSIC) offers the better valuation at 21. 6x trailing P/E (13. 3x forward), making it the more compelling value choice. Analysts rate McKesson Corporation (MCK) a "Buy" — based on 31 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — PINC or OMI or HSIC or MCK or HCAT?
On trailing P/E, Henry Schein, Inc.
(HSIC) is the cheapest at 21. 6x versus Premier, Inc. at 128. 5x. On forward P/E, Owens & Minor, Inc. is actually cheaper at 2. 3x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: McKesson Corporation wins at 0. 49x versus Henry Schein, Inc. 's 4. 21x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.
03Which is the better long-term investment — PINC or OMI or HSIC or MCK or HCAT?
Over the past 5 years, McKesson Corporation (MCK) delivered a total return of +286.
9%, compared to -97. 0% for Health Catalyst, Inc. (HCAT). Over 10 years, the gap is even starker: MCK returned +348. 1% versus HCAT's -95. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — PINC or OMI or HSIC or MCK or HCAT?
By beta (market sensitivity over 5 years), McKesson Corporation (MCK) is the lower-risk stock at 0.
04β versus Health Catalyst, Inc. 's 2. 05β — meaning HCAT is approximately 4645% more volatile than MCK relative to the S&P 500. On balance sheet safety, Health Catalyst, Inc. (HCAT) carries a lower debt/equity ratio of 8% versus 77% for Henry Schein, Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — PINC or OMI or HSIC or MCK or HCAT?
By revenue growth (latest reported year), McKesson Corporation (MCK) is pulling ahead at 16.
2% versus -74. 2% for Owens & Minor, Inc. (OMI). On earnings-per-share growth, the picture is similar: McKesson Corporation grew EPS 14. 9% year-over-year, compared to -201. 1% for Owens & Minor, Inc.. Over a 3-year CAGR, MCK leads at 10. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — PINC or OMI or HSIC or MCK or HCAT?
Henry Schein, Inc.
(HSIC) is the more profitable company, earning 3. 0% net margin versus -57. 2% for Health Catalyst, Inc. — meaning it keeps 3. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: HSIC leads at 5. 7% versus -51. 7% for HCAT. At the gross margin level — before operating expenses — PINC leads at 73. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is PINC or OMI or HSIC or MCK or HCAT more undervalued right now?
The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.
By this metric, McKesson Corporation (MCK) is the more undervalued stock at a PEG of 0. 49x versus Henry Schein, Inc. 's 4. 21x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Owens & Minor, Inc. (OMI) trades at 2. 3x forward P/E versus 20. 8x for Premier, Inc. — 18. 5x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for OMI: 78. 6% to $4. 00.
08Which pays a better dividend — PINC or OMI or HSIC or MCK or HCAT?
In this comparison, PINC (3.
0% yield), MCK (0. 4% yield) pay a dividend. OMI, HSIC, HCAT do not pay a meaningful dividend and should not be held primarily for income.
09Is PINC or OMI or HSIC or MCK or HCAT better for a retirement portfolio?
For long-horizon retirement investors, Premier, Inc.
(PINC) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 07), 3. 0% yield). Health Catalyst, Inc. (HCAT) carries a higher beta of 2. 05 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (PINC: -4. 6%, HCAT: -95. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between PINC and OMI and HSIC and MCK and HCAT?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: PINC is a small-cap quality compounder stock; OMI is a small-cap quality compounder stock; HSIC is a small-cap quality compounder stock; MCK is a mid-cap high-growth stock; HCAT is a small-cap quality compounder stock. PINC pays a dividend while OMI, HSIC, MCK, HCAT do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.